Inflation Data - The core CPI inflation rate in the U.S. fell to 0.06% in March, down 0.17 percentage points from February, significantly below the market expectation of 0.3%[1] - Overall CPI growth turned negative at -0.05% in March, down from 0.22% in February, also below the market expectation of 0.1%[1] - Year-on-year, the overall CPI and core CPI decreased by 0.4 and 0.3 percentage points to 2.4% and 2.8%, respectively[1] Employment Data - Non-farm payrolls increased by 228,000 in March, exceeding market expectations of 140,000 and significantly up from 117,000 in February[2] - The unemployment rate remained stable at 4.15% in March, compared to 4.14% in February[2] Tariff Impact - The weighted average tariff rate in the U.S. increased from 20.5% to 25.9% since Trump's administration, potentially raising inflation by 1.1 to 2.3 percentage points[3] - If the "reciprocal tariff" policy is fully implemented, the inflation impact could rise to 1.4 to 2.7 percentage points[3] Interest Rate Outlook - The forecast remains for 2-3 rate cuts of 25 basis points each throughout the year, although uncertainty due to tariff policies has increased[4] - The Federal Reserve may need to observe the situation before making decisions, as tariffs could push inflation higher[5] Economic Risks - Risks include slow rate cuts leading to recession and the potential for stagflation due to aggressive tariff policies[6]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 60, indicating a potential upside of 55% from the current price of HKD 38.7 [2][5]. Core Insights - The commercialization of CM310 is progressing well, with satisfactory sales performance in the first quarter. The company aims to expand its commercialization team from over 300 to 500 by the end of 2025, focusing on hospital access and negotiations for insurance coverage [3]. - The next-generation dual antibody CM512 is a key product in the research pipeline, with Phase 1 data expected in Q3 2025. The company is also advancing overseas clinical trials for several molecules, with data expected in 2026 [4][10]. - The company has set a sales guidance of RMB 500 million for the year, with significant contributions expected in the second half [3]. Summary by Sections Commercialization Progress - CM310's commercialization team is currently over 300 members, with plans to expand to 500 by the end of 2025. The team is focused on increasing hospital access and engaging with dermatologists and ENT specialists [3]. - The first quarter sales performance was satisfactory, with 29 provinces already having access to CM310. The pricing strategy positions CM310 competitively against existing treatments [3]. Research and Development - CM512, targeting TSLP and IL-13, is in the second position globally for development. The company is focusing on autoimmune and respiratory indications, with ongoing trials in China and plans for international trials [4][10]. - The company anticipates multiple overseas data readouts in 2026, including for CM901 and CM336 [10]. Financial Projections - Revenue is projected to grow significantly, with estimates of RMB 354 million in 2023, increasing to RMB 2.249 billion by 2027, reflecting a compound annual growth rate of 46% [12][14]. - The company expects to incur losses in the coming years, with net losses projected to peak at RMB 737 million in 2026 before improving [12][14].

Core Insights - The report highlights the negative impact of the "reciprocal tariffs" announced by the US, which exceeded market expectations, leading to increased market volatility and heightened risk aversion [3][5][9] - It anticipates a shift in focus back to fundamentals in the Chinese market, with potential for an independent market performance as sentiment improves [3][5] - The report suggests a defensive investment strategy, emphasizing the importance of increasing the weight of dividend-paying stocks in the portfolio [3][31] Market Reaction - Following the announcement of the tariffs, major global markets, including US stocks, experienced significant declines, indicating a rise in risk aversion among investors [3][5] - The report notes that the tariffs could exacerbate the risk of "stagflation" in the US economy, complicating the Federal Reserve's ability to lower interest rates in the near term [3][5] - It emphasizes the need to monitor potential retaliatory measures from other countries and the risk of escalating trade tensions [3][5] Sector Impact - The report identifies sectors that are highly dependent on US imports, such as electronics, machinery, toys, and textiles, as being particularly vulnerable to the increased tariffs [9][12] - It suggests that industries with lower reliance on US imports, such as minerals and food products, will be less affected by the tariff increases [9][12] - The analysis indicates that the profit margins of export-oriented industries in China may be squeezed due to rising tariff costs [9][12] Investment Strategy - In light of increased uncertainty, the report recommends increasing the allocation to dividend-paying stocks, which can provide stable cash flow and mitigate market volatility [3][31] - It advises focusing on sectors with strong cash flow, sustainable dividends, and low valuations while avoiding cyclical industries [31] - If positive signals emerge from tariff negotiations, the report suggests reallocating to technology sectors to enhance growth potential and investment returns [31] Currency Impact - The report warns that the tariff situation may lead to increased volatility in the RMB exchange rate, which could affect market sentiment and capital flows [15][20] - It notes that the A-share market has shown resilience against global economic cycles, with stable liquidity and capital flows [15][20] - The report highlights that sectors with high overseas revenue exposure may be more susceptible to the impacts of US-China trade tensions [15][20] Hong Kong Market Analysis - The report discusses the limited impact of US market fluctuations on the Hong Kong market, suggesting that the latter is more influenced by fundamentals and corporate earnings [25][28] - It points out that the number of export-oriented companies listed in Hong Kong is relatively small, indicating that the direct impact of US tariffs on the Hong Kong market is limited [25][28] - The analysis shows that the correlation between the S&P 500 and the Hang Seng Index has significantly decreased over time, suggesting a diminishing influence of US market movements on Hong Kong stocks [25][27]

Investment Rating - The report maintains a "Buy" rating for Chongqing Beer (600132.CH) with a target price of RMB 69.2, representing a potential upside of 15.7% from the current price of RMB 59.8 [2][5][12]. Core Insights - The report indicates that the weak performance in Q4 2024 was primarily due to the company's proactive inventory clearance, which has now returned to a healthier level. The sales performance in Q1 2025 is expected to be stable, and the company is projected to perform better in 2025 compared to 2024 due to a lower sales base in the second half of the year [1][5]. - The company is adjusting its product and channel structure, which is expected to lead to more positive changes by 2026. The growth of brands like Lebao and regional products is helping to balance the product mix, which has been heavily reliant on the high-end product "Wusu" [1][5][7]. - The report highlights a shift in sales channels, with the on-trade channel's share decreasing from 55% in 2019 to 44% in 2024. The company plans to continue expanding its off-trade channels in 2025, which will help mitigate the impact of declining foot traffic in on-trade channels [5][11]. Financial Performance and Forecast - For 2025, the report forecasts a revenue of RMB 14,937 million, reflecting a 2.0% year-on-year growth, while the net profit is expected to be RMB 1,157 million, a 3.8% increase from 2024 [7][9]. - The average selling price is projected to remain under pressure due to weak market demand for high-end beers, despite a favorable outlook on raw material costs [5][9]. - The report provides a detailed financial forecast, including a projected gross margin of 42.1% for 2025, with a stable cost structure anticipated due to declining barley prices [7][10]. Market Position and Competitive Landscape - The report notes that the company is focusing on enhancing its market share in key cities while maintaining a consistent number of cities covered in 2025. This strategy aims to deepen market penetration and improve brand visibility [5][11]. - The competitive landscape is highlighted, with the company facing challenges from market competition and the need to improve its product structure to sustain growth [5][9].

Policy Overview - The "reciprocal tariffs" policy announced by Trump on April 2, 2025, exceeds market expectations, with a 25% tariff on automobiles effective April 3, 2025[1] - The U.S. government is projected to increase tariff revenue by approximately $600 billion annually, totaling $6 trillion over ten years due to the stringent "reciprocal tariffs" policy[1] Impact on Trade and Economy - The additional 10% tariff on Chinese imports is expected to reduce China's export growth by 10 percentage points and drag down GDP growth by 2 percentage points[2] - Cumulatively, the tariffs could lower China's export growth by 16 percentage points and GDP growth by 3.2 percentage points[4] Inflation and Economic Risks - The tariffs are projected to raise U.S. inflation by 0.41 to 0.82 percentage points, assuming a 50% to 100% pass-through to consumers[5] - The increase in average tariff rates to 10% could further raise U.S. inflation by 0.30 to 0.59 percentage points[5] Tariff Rates by Country - Tariffs on Chinese imports will rise to 67%, with additional tariffs on Southeast Asian countries like Vietnam (90%), Thailand (72%), and Indonesia (64%)[3][8] - Japan and the EU will face tariffs of 46% and 39%, respectively, under the new policy[3][8] Long-term Outlook - The high tariff rates are not expected to be permanent, as they may serve as leverage for negotiations with trade partners[6] - Risks include potential economic stagnation or recession in the U.S. due to the aggressive tariff policies[6]

Investment Rating - The report maintains a "Buy" rating for the company, Yangjie Technology, with a target price raised to RMB 55.7, indicating a potential upside of 20% from the current price of RMB 46.3 [2][8]. Core Insights - Yangjie Technology is expected to continue its growth momentum into 2025, following a trend of improving revenue, gross margin, and net profit throughout 2024, outperforming the overall power industry [2][3]. - Despite a temporary adjustment in demand for new energy sources like photovoltaics, strong growth is anticipated in automotive electronics, consumer sectors, and overseas markets, supported by national policies and market recovery [2][3]. - The company plans to acquire Dongguan Better to enhance its product lineup in circuit protection components, which is expected to contribute to long-term growth in automotive electronics, AI servers, and international markets [2][3]. Financial Performance and Forecast - In Q4 2024, Yangjie Technology achieved revenue of RMB 1.61 billion, a year-on-year increase of 18%, with a gross margin of 38.7%, marking a significant improvement [3][14]. - The company’s net profit for Q4 2024 was RMB 330 million, reflecting an 8% year-on-year growth and a 35% increase from the previous quarter [3][14]. - The financial projections for 2025 estimate revenue of RMB 7.01 billion, a 16% increase from 2024, with net profit expected to reach RMB 1.23 billion, representing a 23% growth [5][15]. Valuation - The report employs a DCF valuation method, assuming a risk-free rate of 1.8% and a growth rate of 15% for 2030-2034, resulting in a target price of RMB 55.7 [4]. - The current price-to-earnings ratio for Yangjie Technology is noted at 20.6x, which is considered attractive compared to historical averages [4][20].

Investment Rating - The report maintains a "Buy" rating for China Feihe (6186.HK) with a target price of HKD 6.65, indicating a potential upside of 13.3% from the current price of HKD 5.87 [3][6]. Core Insights - China Feihe's net profit for 2H24 fell short of market expectations due to short-term inventory clearance in functional nutrition products, including adult milk powder, which affected overall gross margin performance. However, the infant formula business showed revenue growth in line with expectations, and profit margins remained robust. Management is confident that revenue growth in 2025 will exceed that of 2024, with a slight increase in gross margin expected year-on-year [1][6]. - The company is positioned as a leader in the infant formula market, driving industry consolidation trends. The report suggests that Feihe will continue to capture market share through increased brand investment and product innovation [1][6]. Financial Performance and Projections - Revenue for 2023 was reported at RMB 19,532 million, with a projected increase to RMB 20,749 million in 2024, reflecting a year-on-year growth of 6.2%. The forecast for 2025 anticipates revenue of RMB 21,817 million, representing a growth of 5.1% [8][11]. - The net profit for 2023 was RMB 3,390 million, with expectations of growth to RMB 3,570 million in 2024 and RMB 3,944 million in 2025, indicating a year-on-year increase of 5.3% and 10.5%, respectively [8][11]. - The gross margin is expected to improve from 64.8% in 2023 to 66.3% in 2024, with further stability projected for 2025 [8][11]. Market Position and Strategy - China Feihe is focusing on high-end product offerings, with ultra-high-end products expected to see a revenue increase of 17% in 2024, contributing to 69% of total revenue. The company plans to launch even higher-end products in 2H25 [6][11]. - The management has announced a RMB 12 billion maternity subsidy plan, which is expected to have a limited negative impact on profit margins, as the actual costs will be lower than the total subsidy amount [6][11]. Dividend Policy - The company has increased its dividend payout, with a projected dividend of HKD 0.3264 per share for 2024, raising the payout ratio to 76.1%. Management aims for a 10% annual increase in absolute dividend amounts over the next two years [6][11].

Investment Rating - The report maintains a "Buy" rating for BYD [6] Core Views - BYD is expected to significantly increase its smart driving penetration rate, driving substantial growth in both sales and profits for new energy vehicles [2][6] - The target price for BYD shares is set at HKD 481.0, representing a potential upside of 18% for the Hong Kong stock and CNY 469.0 for the A-share, with a potential upside of 21% [4][5] Financial Forecasts - Revenue is projected to grow from RMB 602,315 million in 2023 to RMB 966,125 million in 2025, reflecting a compound annual growth rate (CAGR) of 24% [3][9] - Net profit is expected to increase from RMB 30,041 million in 2023 to RMB 50,211 million in 2025, with a net profit growth rate of 25% [3][9] - The gross margin is forecasted to decline slightly from 20.2% in 2023 to 18.7% in 2025 [3][9] Sales and Market Performance - BYD's vehicle sales are anticipated to reach 5.5 million units in 2025, with overseas sales expected to nearly double [6] - The sales of high-end brands such as Tengshi, Fangchengbao, and Yangwang are projected to grow significantly [6] Valuation - The report employs a sum-of-the-parts valuation method, assigning price-to-earnings ratios of 29.0x for new energy vehicles, 21.0x for mobile and electronic businesses, and 10.0x for other businesses, leading to target prices of HKD 481.0 and CNY 469.0 [10]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 7.5 HKD, indicating that the current market price does not reflect the company's true value [1][4]. Core Insights - The company is expected to steadily reduce losses in 2024, with the neurointervention segment achieving its first annual profit. Revenue for 2024 is projected at 615 million RMB, a 40% year-over-year increase, with a gross margin of 70.5% [2][4]. - The cardiac valve segment is anticipated to generate 260 million RMB in revenue for 2024, also reflecting a 40% year-over-year growth, while the neurointervention segment is expected to reach 356 million RMB, marking a 39% increase [2][3]. - The report highlights that the market is closely monitoring the impact of centralized procurement, particularly in the neurointervention field, where risks are nearing resolution. In the cardiac valve sector, the slowdown in implant volume growth may not necessarily be negative due to potential price adjustments post-procurement [3][4]. Financial Performance Summary - Revenue projections for the company are as follows: 441 million RMB in 2023, 615 million RMB in 2024, 821 million RMB in 2025, 781 million RMB in 2026, and 1,024 million RMB in 2027, with year-over-year growth rates of 75.9%, 39.5%, 33.4%, -4.9%, and 31.2% respectively [5][12]. - The company is expected to narrow its net loss from 393 million RMB in 2023 to 228 million RMB in 2024, with further reductions anticipated in subsequent years [5][12]. - The report provides a detailed breakdown of revenue by segment, with cardiac valves and neurointervention contributing significantly to the overall growth [2][12]. Product Pipeline and Market Strategy - The company has separated three advanced products from its transcatheter valve business to prepare for independent financing and international expansion. These products are aimed at the European and American markets [4][14]. - The DCWire microguidewire is currently undergoing FDA registration and is expected to be the company's first original product to enter the international market [4][14]. - The report outlines the expected approval timelines for various products, including the TaurusNXT and TaurusTrio, which are anticipated to receive approval between late 2025 and mid-2026 [4][14].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 88.9, indicating a potential upside of 18% from the current price of HKD 75.25 [1][3]. Core Insights - The company is expected to see strong growth in its business guidance for 2025, with significant profit increases anticipated. The mobile camera module and lens segments are projected to outperform industry growth rates, contributing to improved profitability [10]. - The automotive segment is also expected to maintain robust growth, with revenue increases providing stable profit growth. The net profit for 2025 is forecasted to grow by 22% year-on-year [10]. - The report highlights an upward revision of profit forecasts for 2025 and 2026 based on the company's performance and outlook [10]. Financial Projections - Revenue is projected to grow from RMB 31,681 million in 2023 to RMB 50,842 million by 2027, with a compound annual growth rate (CAGR) of approximately 10% [2]. - The gross margin is expected to improve from 14.5% in 2023 to 20.2% in 2027, reflecting enhanced profitability [2]. - Net profit is anticipated to rise from RMB 1,099 million in 2023 to RMB 4,610 million in 2027, with a significant increase in growth rates, particularly a 146% increase in 2024 [2]. Segment Performance - The mobile camera module segment is expected to generate revenue of RMB 21,038 million in 2025, with a net profit of RMB 600 million [14]. - The automotive lens segment is projected to achieve a revenue of RMB 4,390 million in 2025, with a net profit of RMB 741 million [14]. - The overall revenue for the company in 2025 is estimated at RMB 41,677 million, with a net profit of RMB 3,306 million [14].